Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data

Angela B. Brueggemann(University of Oxford), Melissa J. Jansen van Rensburg(University of Oxford), David R. Shaw(University of Oxford), Noel McCarthy(Trinity College Dublin), Keith A. Jolley(University of Oxford), Martin Maiden(University of Oxford), Mark P. G. van der Linden(RWTH Aachen University), Zahin Amin‐Chowdhury(Public Health England), Désirée E. Bennett(Beaumont Hospital), Ray Borrow(Manchester Royal Infirmary), Maria-Cristina C Brandileone(Instituto Adolfo Lutz), Karen Broughton(Public Health England), Ruth Campbell, Bin Cao(Chinese Academy of Medical Sciences & Peking Union Medical College), Carlo Casanova(University of Bern), Eun Hwa Choi(Seoul National University), Yiu Wai Chu(Department of Health), S. A. Clark(Public Health England), Heike Claus(University of Würzburg), Juliana Coelho(Public Health England), Mary Corcoran(Children's Health Ireland at Crumlin), Simon Cottrell(Public Health Wales), Robert Cunney(Beaumont Hospital), Tine Dalby(Statens Serum Institut), Heather Davies(New Zealand Institute for Public Health and Forensic Science), Linda de Gouveia(National Health Laboratory Service), Ala‐Eddine Deghmane(Institut Pasteur), Walter Demczuk(Public Health Agency of Canada), Stefanie Desmet(KU Leuven), Richard J. Drew(Royal College of Surgeons in Ireland), Mignon du Plessis(National Health Laboratory Service), Helga Erlendsdóttir(National University Hospital of Iceland), Norman K. Fry(Public Health England), Kurt Fuursted(Statens Serum Institut), Steve Gray(Public Health England), Birgitta Henriques‐Normark(Karolinska University Hospital), Thomas Hale(University of Oxford), Markus Hilty(University of Bern), Steen Hoffmann(Statens Serum Institut), H. Humphreys(Beaumont Hospital), Margaret Ip(Chinese University of Hong Kong), Susanne Jacobsson(Örebro University), Jillian Johnston, Jana Kozáková(National Institute of Public Health), Karl G. Kristinsson(National University Hospital of Iceland), Pavla Křížová(National Institute of Public Health), Alicja Kuch(Narodowy Instytut Leków), Shamez Ladhani(Public Health England), Thiên‐Trí Lâm(University of Würzburg), Vera Lebedova(National Institute of Public Health), Laura Lindholm(Finnish Institute for Health and Welfare), David Litt(Public Health England), Irene Martín(Public Health Agency of Canada), Delphine Martiny(University of Mons), Wesley Mattheus(Sciensano (Belgium)), Martha McElligott(Beaumont Hospital), Mary Meehan(Beaumont Hospital), Susan Meiring(National Health Laboratory Service), Paula Mölling(Örebro University), Eva Morfeldt(Public Health Agency of Sweden), Julie Morgan(New Zealand Institute for Public Health and Forensic Science), Robert Mulhall(Beaumont Hospital), Carmen Muñoz‐Almagro(Hospital Sant Joan de Déu Barcelona), David R. Murdoch(University of Otago), Joy Murphy, Martin Musílek(National Institute of Public Health), A. Mzabi(Laboratoire National de Santé), Amaresh Pérez-Argüello(Hospital Sant Joan de Déu Barcelona), Monique Perrin(Laboratoire National de Santé), Malorie Perry(Public Health Wales), Alba Redin(Hospital Sant Joan de Déu Barcelona), Richard J. Roberts(Public Health Wales), Maria Roberts(Public Health Wales), Assaf Rokney(Israel Ministry of Health), M. Ron(Israel Ministry of Health), Kevin J Scott, Carmen Sheppard(Public Health England), Lotta Siira(Finnish Institute for Health and Welfare), Anna Skoczyńska(Narodowy Instytut Leków), Monica Sloan, Hans‐Christian Slotved(Statens Serum Institut), Andrew Smith, Joon Young Song(Korea University Medical Center), Muhamed-Kheir Taha(Institut Pasteur), Maija Toropainen(Finnish Institute for Health and Welfare), Dominic N.C. Tsang(Department of Health), Anni Vainio(Finnish Institute for Health and Welfare), Nina M. van Sorge(University of Amsterdam), Emmanuelle Varon(Hôpital Intercommunal de Créteil), J. Vlach(National Institute of Public Health), Ulrich Vogel(University of Würzburg), Sandra Vohrnova(National Institute of Public Health), Anne von Gottberg(National Health Laboratory Service), Rosemeire Cobo Zanella(Instituto Adolfo Lutz), Fei Zhou(China-Japan Friendship Hospital)
The Lancet Digital Health
May 24, 2021
Cited by 530Open Access
Full Text

Abstract

BACKGROUND: Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, which are typically transmitted via respiratory droplets, are leading causes of invasive diseases, including bacteraemic pneumonia and meningitis, and of secondary infections subsequent to post-viral respiratory disease. The aim of this study was to investigate the incidence of invasive disease due to these pathogens during the early months of the COVID-19 pandemic. METHODS: In this prospective analysis of surveillance data, laboratories in 26 countries and territories across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae, and N meningitidis from Jan 1, 2018, to May, 31, 2020, as part of the Invasive Respiratory Infection Surveillance (IRIS) Initiative. Numbers of weekly cases in 2020 were compared with corresponding data for 2018 and 2019. Data for invasive disease due to Streptococcus agalactiae, a non-respiratory pathogen, were collected from nine laboratories for comparison. The stringency of COVID-19 containment measures was quantified using the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed using Google COVID-19 Community Mobility Reports. Interrupted time-series modelling quantified changes in the incidence of invasive disease due to S pneumoniae, H influenzae, and N meningitidis in 2020 relative to when containment measures were imposed. FINDINGS: 27 laboratories from 26 countries and territories submitted data to the IRIS Initiative for S pneumoniae (62 837 total cases), 24 laboratories from 24 countries submitted data for H influenzae (7796 total cases), and 21 laboratories from 21 countries submitted data for N meningitidis (5877 total cases). All countries and territories had experienced a significant and sustained reduction in invasive diseases due to S pneumoniae, H influenzae, and N meningitidis in early 2020 (Jan 1 to May 31, 2020), coinciding with the introduction of COVID-19 containment measures in each country. By contrast, no significant changes in the incidence of invasive S agalactiae infections were observed. Similar trends were observed across most countries and territories despite differing stringency in COVID-19 control policies. The incidence of reported S pneumoniae infections decreased by 68% at 4 weeks (incidence rate ratio 0·32 [95% CI 0·27-0·37]) and 82% at 8 weeks (0·18 [0·14-0·23]) following the week in which significant changes in population movements were recorded. INTERPRETATION: The introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of S pneumoniae, H influenzae, and N meningitidis, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide. FUNDING: Wellcome Trust (UK), Robert Koch Institute (Germany), Federal Ministry of Health (Germany), Pfizer, Merck, Health Protection Surveillance Centre (Ireland), SpID-Net project (Ireland), European Centre for Disease Prevention and Control (European Union), Horizon 2020 (European Commission), Ministry of Health (Poland), National Programme of Antibiotic Protection (Poland), Ministry of Science and Higher Education (Poland), Agencia de Salut Pública de Catalunya (Spain), Sant Joan de Deu Foundation (Spain), Knut and Alice Wallenberg Foundation (Sweden), Swedish Research Council (Sweden), Region Stockholm (Sweden), Federal Office of Public Health of Switzerland (Switzerland), and French Public Health Agency (France).


Related Papers

No related papers found

Powered by citation graph analysis